Calman A. MacLennan
BM, BCh, DPhil, FHEA, FRCP, FRCPath
Professor of Vaccine Immunology (University of Birmingham)
- Jenner Investigator and Group Leader - Gonococcal Vaccine Project, Jenner Institute
- Director of BactiVac, the Bacterial Vaccines Network, Institute of Immunology and Immunotherapy, University of Birmingham, UK
- Consultant Immunologist, Oxford University Hospitals NHS Foundation Trust, UK
- Senior Program Officer, Bacterial Vaccines, Global Health, Enteric & Diarrheal Diseases, Bill & Melinda Gates Foundation, Seattle, US
Vaccinologist, Immunologist & Clinician Scientist focused on bacterial infections and AMR
Calman MacLennan is a clinician scientist, vaccinologist and immunologist who joined the Jenner Institute in 2015. For the past 25 years, his career has focused on understanding mechanisms of immunological of protection against bacterial infections of global health significance and antimicrobial resistance (AMR) concern. This knowledge has then been applied to the development of protective vaccines.
With experience of vaccine development in academia and industry, he has been involved in the development of several bacterial vaccines including one licensed vaccine against typhoid and other vaccines currently in clinical trials.
He leads the Gonococcal Vaccine Project which is using native Outer Membrane Vesicle (nOMV) technology to develop a candidate vaccine against Neisseria gonorrhoeae, the causative agent of gonorrhoea. Gonorrhoea infects 82.4 million people each year and is rapidly becoming resistant to all known antibiotics.
Professor MacLennan is the founder and director of BactiVac, the Bacterial Vaccines Network, a worldwide network based out of the University of Birmingham with a mission to accelerate the development of vaccines against bacterial pathogens as a countermeasure to AMR. He is a Consultant Immunologist at the Oxford University Hospitals NHS Foundation Trust.
Key publications
-
Impact and Control of Sugar Size in Glycoconjugate Vaccines.
Journal article
Stefanetti G. et al, (2022), Molecules (Basel, Switzerland), 27
-
The Shigella Vaccines Pipeline.
Journal article
MacLennan CA. et al, (2022), Vaccines, 10
-
Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data.
Journal article
Cohen D. et al, (2022), Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
-
Critical needs in advancing Shigella vaccines for global health
Journal article
MacLennan CA. et al, (2021), The Journal of Infectious Diseases
-
Outer membrane vesicle vaccines
Journal article
Micoli F. and MacLennan CA., (2020), Seminars in Immunology, 50, 101433 - 101433
-
Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM197 conjugate vaccine.
Journal article
Micoli F. et al, (2020), Proceedings of the National Academy of Sciences of the United States of America, 117, 24443 - 24449
-
Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella.
Journal article
Micoli F. et al, (2018), Proc Natl Acad Sci U S A, 115, 10428 - 10433
-
Presentation of life-threatening invasive nontyphoidal Salmonella disease in Malawian children: A prospective observational study.
Journal article
MacLennan CA. et al, (2017), PLoS Negl Trop Dis, 11
-
Contribution of factor H-Binding protein sequence to the cross-reactivity of meningococcal native outer membrane vesicle vaccines with over-expressed fHbp variant group 1.
Journal article
Marini A. et al, (2017), PLoS One, 12
-
Cytokine Profiles in Malawian Children Presenting with Uncomplicated Malaria, Severe Malarial Anemia, and Cerebral Malaria.
Journal article
Mandala WL. et al, (2017), Clin Vaccine Immunol, 24
-
Characterization of O-antigen delivered by Generalized Modules for Membrane Antigens (GMMA) vaccine candidates against nontyphoidal Salmonella.
Journal article
De Benedetto G. et al, (2017), Vaccine, 35, 419 - 426
-
A Systematic Review of the Incidence, Risk Factors and Case Fatality Rates of Invasive Nontyphoidal Salmonella (iNTS) Disease in Africa (1966 to 2014).
Journal article
Uche IV. et al, (2017), PLoS Negl Trop Dis, 11
-
Brief Report: Immunization of HIV-Infected Adults in the UK With Haemophilus influenzae b/Meningococcal C Glycoconjugate and Pneumococcal Polysaccharide Vaccines.
Journal article
MacLennan CA. et al, (2016), J Acquir Immune Defic Syndr, 73, 287 - 293
-
Cytokine Profiles during Invasive Nontyphoidal Salmonella Disease Predict Outcome in African Children.
Journal article
Gilchrist JJ. et al, (2016), Clin Vaccine Immunol, 23, 601 - 609
-
Bactericidal Immunity to Salmonella in Africans and Mechanisms Causing Its Failure in HIV Infection.
Journal article
Goh YS. et al, (2016), PLoS Negl Trop Dis, 10
-
Monoclonal Antibodies of a Diverse Isotype Induced by an O-Antigen Glycoconjugate Vaccine Mediate In Vitro and In Vivo Killing of African Invasive Nontyphoidal Salmonella.
Journal article
Goh YS. et al, (2015), Infect Immun, 83, 3722 - 3731
-
Genetic susceptibility to invasive Salmonella disease.
Journal article
Gilchrist JJ. et al, (2015), Nat Rev Immunol, 15, 452 - 463
-
A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA).
Journal article
Koeberling O. et al, (2014), Vaccine, 32, 2688 - 2695
-
Design of glycoconjugate vaccines against invasive African Salmonella enterica serovar Typhimurium.
Journal article
Rondini S. et al, (2015), Infect Immun, 83, 996 - 1007
-
Vaccines against poverty.
Journal article
MacLennan CA. and Saul A., (2014), Proc Natl Acad Sci U S A, 111, 12307 - 12312
-
Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.
Journal article
Micoli F. et al, (2013), Proc Natl Acad Sci U S A, 110, 19077 - 19082
-
Dysregulated humoral immunity to nontyphoidal Salmonella in HIV-infected African adults.
Journal article
MacLennan CA. et al, (2010), Science, 328, 508 - 512
-
Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal Salmonella by blood cells in Africans.
Journal article
Gondwe EN. et al, (2010), Proc Natl Acad Sci U S A, 107, 3070 - 3075
-
The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children.
Journal article
MacLennan CA. et al, (2008), J Clin Invest, 118, 1553 - 1562